|
- DoesCorrection ofSecondary Hyperparathyroidism withExtended-Release . . .
Received: September 19, 2024 Accepted: September 23, 2024 Published online: October 24, 2024 DoesCorrection ofSecondary randomized trial comparing subtotal PTX with cina- centrations with extended-release calcifediol slows chronic kidney disease progression in secondary hyperparathyroidism patients Am
- Calcifediol Oral Capsule in Chronic Kidney Diseases and Vitamin D . . .
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 (calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism (SHPT) in Subjects with Vitamin D Insufficiency (VDI) and Chronic Kidney Disease Requiring Regular Hemodialysis
- Calcifediol Completed Phase 4 Trials for Stage 4 Chronic Kidney Disease . . .
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency: Calcifediol (DB00146) Cholecalciferol (DB00169)
- Real-world assessment: effectiveness and safety of extended-release . . .
Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3–4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI) Their effectiveness for increasing serum total 25-hydroxyvitamin D (25D) and reducing elevated plasma parathyroid
- Extended-release calcifediol in stage 3–4 chronic kidney disease: a new . . .
A high percentage of patients with chronic kidney disease have hypovitaminosis D, which is a driver of secondary hyperparathyroidism and an important factor in chronic kidney disease-mineral and bone disorder Vitamin D deficiency (serum total 25-OH vitamin D levels < 30 ng mL) occurs early in the course of chronic kidney disease and treatment guidelines recommend early intervention to restore
- Real-World Assessment: Clinical Effectiveness and Safety of . . . - Rayaldee
Chronic kidney disease (CKD) is a major and growing global health burden and is projected to be one of the top 4 leading causes of lost potential years of life by 2040 [1] In the United States (US), CKD prevalence and mortality rates have been rising in recent years According to the US Renal Data System, nearly 50 million people (14 9%
- High-dose extended-release calcifediol successfully treated advanced . . .
Background: This unprecedented case report supports three important conclusions pertinent to the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD): (1) serum 25-hydroxyvitamin D (25D) repletion can effectively reduce elevated intact parathyroid hormone (iPTH) in advanced CKD; (2) serum total 25D levels required for effective iPTH reduction are much
- Calcifediol – Application in Therapy and Current Clinical Research
Kidney Health: Studies are looking at whether calcifediol can help prevent or reduce the severity of sudden kidney damage in critically ill patients Asthma Control : Some research is exploring whether calcifediol supplementation can help improve asthma control in patients with vitamin D deficiency [5]
|
|
|